비교리스트

 카트 문의
시장보고서
상품코드
1566764

척추 생물학적 제제 시장 : 제품별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 280 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

척추 생물학적 제제 시장

척추 생물학적 제제 시장은 2023년 30억 5,000만 달러로 평가되며 2024-2035년 연평균 5.29%의 CAGR을 기록해 2035년에는 55억 5,000만 달러에 달할 것으로 추정됩니다.

척추 생물학적 제제는 척추의 유합을 촉진하고 치유를 촉진하며 일부 척추 질환을 치료하는 재료로 구성됩니다. 이 재료에는 성장 인자, 줄기세포 및 골이식편이 포함되어 신체의 자연 치유 과정을 돕습니다. 골이식편은 새로운 뼈의 성장에 필요한 발판입니다. 골이식에는 환자 자신의 몸에서 유래한 자가 이식편과 기증자에서 유래한 동종 이식편이 있습니다. 줄기세포는 완전한 기능을 가진 새로운 세포를 생성할 수 있는 능력을 가진 특수한 세포이며, 골형성단백질(BMP)과 같은 성장인자는 재생과 뼈 복구를 위해 세포를 자극하는 역할을 합니다. 척추 생물학적 제제의 사용은 두 개 이상의 척추를 접합하는 척추 고정술에서 널리 사용되고 있습니다.

척추 질환의 유병률 증가, 특히 급증하는 노인 인구의 증가는 척추 생물학적 제제 시장의 주요 촉진요인입니다. 또한, 최소침습 수술에 대한 선호도가 높아지면서 척추 수술 시 침습을 최소화하고 치유를 촉진하는 척추 생물학적 제제에 대한 수요가 급증하고 있습니다. 최근 트렌드에 따르면, 골이식 대체물 개발에 적층 제조법을 사용하는 것이 시장의 새로운 트렌드가 되고 있습니다. 이러한 대체품은 생체 거부반응의 가능성이 있는 골이식편과 비교하여 동등한 효과와 개선된 안전성을 가지고 있습니다.

그러나 척추 생물학적 제제 개발은 복잡한 과정과 높은 비용으로 인해 시장 발전을 저해하고 있습니다. 또한, 척추 수술에 대한 충분한 보험이 적용되지 않는 비효율적인 상환 정책은 고가의 치료를 받는 것을 주저하게 만들어 시장 성장을 제한하고 있습니다. 반대로 척추 손상 건수는 지속적으로 증가하고 있으며, 이는 향후 척추 생물학적 제제에 대한 수요를 촉진할 것으로 예상됩니다. 미국 국립의학도서관이 최근 발표한 논문에 따르면, 미국에서 매년 새로 발생하는 척수 손상의 38%가 자동차 사고로 인한 것이며, 낙상은 척수 손상의 두 번째로 많은 원인으로 전체의 30%를 차지한다고 합니다.

부문별 리뷰

척추 생물학적 제제 시장은 제품, 최종사용자, 지역으로 구분됩니다. 제품별로는 척추 동종 이식편, 골이식 대체물, 세포 기반 매트릭스로 나뉩니다. 최종사용자별로는 병원과 외래환자용 시설로 구분됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

제품별로는 척추 이식 부문이 2023년 시장을 장악했습니다.

최종사용자별로는 병원 부문이 2023년 시장에서 가장 높은 점유율을 차지했습니다.

지역별로는 북미가 2035년까지 가장 높은 수익을 올릴 것으로 예상됩니다.

이 보고서는 사용자 정의가 가능합니다.

  • 규제 가이드라인
  • 고객의 관심사에 따른 기업 프로파일 추가
  • 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
  • 기업 개요 확대 목록
  • 과거 시장 데이터
  • 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 기회
    • 주요 성공 전략
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회

제4장 척추 생물학적 제제 시장 : 제품별

  • 시장 개요
  • 척추 이식편
  • 골이식 대체물
  • 세포 기반 매트릭스

제5장 척추 생물학적 제제 시장 : 최종사용자별

  • 시장 개요
  • 병원
  • 외래 환자 시설

제6장 척추 생물학적 제제 시장 : 지역별

  • 시장 개요
  • 북미
    • 주요 시장 동향과 기회
    • 미국의 척추 생물학적 제제 시장
    • 캐나다의 척추 생물학적 제제 시장
    • 멕시코의 척추 생물학적 제제 시장
  • 유럽
    • 주요 시장 동향과 기회
    • 독일의 척추 생물학적 제제 시장
    • 프랑스의 척추 생물학적 제제 시장
    • 영국의 척추 생물학적 제제 시장
    • 이탈리아의 척추 생물학적 제제 시장
    • 스페인의 척추 생물학적 제제 시장
    • 기타 유럽의 척추 생물학적 제제 시장
  • 아시아태평양
    • 주요 시장 동향과 기회
    • 일본의 척추 생물학적 제제 시장
    • 중국의 척추 생물학적 제제 시장
    • 호주의 척추 생물학적 제제 시장
    • 인도의 척추 생물학적 제제 시장
    • 한국의 척추 생물학적 제제 시장
    • 기타 아시아태평양의 척추 생물학적 제제 시장
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향과 기회
    • 브라질의 척추 생물학적 제제 시장
    • 사우디아라비아의 척추 생물학적 제제 시장
    • 남아프리카공화국의 척추 생물학적 제제 시장
    • 기타 라틴아메리카, 중동 및 아프리카의 척추 생물학적 제제 시장

제7장 경쟁 상황

  • 소개
  • 주요 성공 전략
  • 주요 10개 기업 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝(2023년)

제8장 기업 개요

  • Stryker Corporation
  • NuVasive, Inc.
  • Orthofix
  • Johnson And Johnson
  • Exactech, Inc
  • Zimmer Biomet Holding, Inc.
  • Arthrex, Inc.
  • Medtronic Plc
  • Organogenesis Inc
  • Kuros Biosciences
ksm 24.10.16

Spine Biologics Market

The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.

Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.

Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.

However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.

Segment Review

The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product, the spinal allografts segment dominated the market in 2023.

As per end user, the hospital segment acquired a high stake in the market in 2023.

Region wise, North America is projected to be the highest revenue generator by 2035.

Competition Analysis

The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

  • Spinal Allografts
  • Bone Graft Substitutes
  • Cell-Based Matrix

By End User

  • Hospitals
  • Outpatient Facilities

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Stryker Corporation
    • NuVasive, Inc.
    • orthofix
    • Johnson & Johnson
    • Exactech, Inc
    • Zimmer Biomet Holding, Inc.
    • Arthrex, Inc.
    • Medtronic plc
    • Organogenesis Inc
    • Kuros Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product
  • 4.2. Spinal Allografts
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Bone Graft Substitutes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Cell-Based Matrix
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Outpatient Facilities
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Spine Biologics Market
      • 6.2.5.1. Market Size and Forecast, By Product
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Spine Biologics Market
      • 6.2.6.1. Market Size and Forecast, By Product
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Spine Biologics Market
      • 6.2.7.1. Market Size and Forecast, By Product
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Spine Biologics Market
      • 6.3.5.1. Market Size and Forecast, By Product
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Spine Biologics Market
      • 6.3.6.1. Market Size and Forecast, By Product
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Spine Biologics Market
      • 6.3.7.1. Market Size and Forecast, By Product
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Spine Biologics Market
      • 6.3.8.1. Market Size and Forecast, By Product
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Spine Biologics Market
      • 6.3.9.1. Market Size and Forecast, By Product
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Spine Biologics Market
      • 6.3.10.1. Market Size and Forecast, By Product
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Spine Biologics Market
      • 6.4.5.1. Market Size and Forecast, By Product
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Spine Biologics Market
      • 6.4.6.1. Market Size and Forecast, By Product
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Spine Biologics Market
      • 6.4.7.1. Market Size and Forecast, By Product
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Spine Biologics Market
      • 6.4.8.1. Market Size and Forecast, By Product
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Spine Biologics Market
      • 6.4.9.1. Market Size and Forecast, By Product
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Spine Biologics Market
      • 6.4.10.1. Market Size and Forecast, By Product
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Spine Biologics Market
      • 6.5.5.1. Market Size and Forecast, By Product
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Spine Biologics Market
      • 6.5.6.1. Market Size and Forecast, By Product
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Spine Biologics Market
      • 6.5.7.1. Market Size and Forecast, By Product
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Spine Biologics Market
      • 6.5.8.1. Market Size and Forecast, By Product
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Stryker Corporation
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. NuVasive, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Orthofix
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Johnson And Johnson
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Exactech, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Zimmer Biomet Holding, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Arthrex, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Medtronic Plc
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Organogenesis Inc
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Kuros Biosciences
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제